NIH Scientists Reactivate Immune Cells Exhausted by Chronic HIV
June 3, 2011
WHAT: Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National
Institutes of Health, have demonstrated why certain immune cells chronically exposed to HIV shut down, and how they can be reactivated.
Healthy B cells have a balanced mix of surface proteins that the immune system can use, like the gas pedal and brake of a car, either
to activate the cell or to damp down its activity. However, in people with long-term HIV infection who have not begun antiretroviral
therapy, their B cells-responsible for producing anti-HIV antibodies-display a surplus of inhibitory receptors, the surface proteins
used to apply the brakes on a B cell. Scientists from the NIAID Laboratory of Immunoregulation led by Lela Kardava, Ph.D.,
Susan Moir, Ph.D., and Anthony S. Fauci, M.D., NIAID Director and Chief of the laboratory, wanted to know if this
phenomenon can help explain why B cells become "exhausted" and essentially shut down in people who are HIV-infected but treatment-naive.
To test their hypothesis, the scientists used molecules called small interfering RNAs (siRNAs), which acted at the genetic level to
prevent exhausted B cells from replenishing inhibitory receptors. After treatment with siRNAs, the exhausted cells responded more
normally to conditions that typically would spur a B cell into action, such as the presence of a virus, demonstrating that the
excess of inhibitory receptors may explain why exhausted B cells are so unresponsive.
Because B cells generally are difficult to manipulate, the new siRNA-based approach may hold promise for scientists seeking to
develop therapies to improve the human antibody response against HIV and other pathogens by altering the expression of specific
L Kardava et al . Attenuation of HIV-associated human B cell exhaustion by siRNA downregulation of inhibitory receptors. The
Journal of Clinical Investigation DOI:10.1172/JCI45685 (2011).
Anthony S. Fauci, M.D., NIAID Director and Chief, NIAID Laboratory of Immunoregulation; and Susan Moir, Ph.D., Staff Scientist,
NIAID Laboratory of Immunoregulation, are available to comment on this article.
To schedule interviews, please contact Laura Sivitz Leifman, 301-402-1663 , email@example.com .
NIAID conducts and supports research-at NIH, throughout the United States, and worldwide-to study the causes of infectious
and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News
releases, fact sheets and other NIAID-related materials are available on the NIAID Web site
at http://www.niaid.nih.gov/ .
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and
is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting
basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common
and rare diseases. For more information about NIH and its programs,
visit http://www.nih.gov/ .